Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Disparities

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

NST showed stable cross-cohort structure (Mantel r = 0.71-0.77) and differentiated MCI (d = -0.39) and AD biomarker status (d = -0.23). NST tracked longitudinal cognitive change, correlated with hippocampal volume (r up to 0.28, P < .001), and showed smaller racial and educational disparities relative to standard cognitive testing (NST d = 0.03-0.33, MoCA d = 0.37-0.72). NST provides a validated neurocognitive construct that facilitates interpretation of AI-driven voice biomarkers of AD. This study was not registered in a public trials registry.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 1,479 participants. This study developed a speech-based measure that distinguished people with mild cognitive impairment and Alzheimer's biomarker status, and tracked cognitive change over time. It also showed smaller disparities by race and education than standard cognitive tests, but it is a measurement tool, not a treatment.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Henley, B., Yang, Z., Sober, J., Calhoun, V., Goldstein, F., & Hajjar, I. (2026). A neurocognitive speech taxonomy for voice biomarkers of Alzheimer's disease. medRxiv (preprint). https://doi.org/10.64898/2026.09.23.26363671

Vancouver

Henley B, Yang Z, Sober J, Calhoun V, Goldstein F, Hajjar I. A neurocognitive speech taxonomy for voice biomarkers of Alzheimer's disease. medRxiv (preprint). 2026. doi:10.64898/2026.09.23.26363671.

BibTeX

@article{henley2026-0e2d31c9,
  author  = {Henley, B. and Yang, Z. and Sober, J. and Calhoun, V. and Goldstein, F. and Hajjar, I.},
  title   = {{A neurocognitive speech taxonomy for voice biomarkers of Alzheimer's disease}},
  journal = {medRxiv (preprint)},
  year    = {2026},
  doi     = {10.64898/2026.09.23.26363671},
  url     = {https://doi.org/10.64898/2026.09.23.26363671}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This study developed a speech-based measure that distinguished people with mild cognitive impairment and Alzheimer's biomarker status, and tracked cognitive change over time. It also showed smaller disparities by race and education than standard cognitive tests, but it is a measurement tool, not a treatment.

Study details

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 4 of 10; How recent 5 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. 34 of the 90 points it could be judged on, which is 38 of 100. Raw total 38 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 38 of 100capped at 16 — hatched points do not count

Preprint — not yet peer-reviewed. It scored 38 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on impact for its field and year and senior author's track record, so those were left out: it earned 34 of the 90 points we could judge it on, which is 38 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (medRxiv (preprint))
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 4 / 10 Preprint — not yet peer-reviewed. Hosted on a preprint server.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 3 / 4 1,479 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Ihab Hajjar holds only 8 work(s), too few to judge a track record — left out of this score
Institution's track record 2 / 3 Baylor College of Medicine: institution h-index 1,607 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Points 34 / 90 Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 34 of the 90 points we could judge it on is 38 out of 100.
Total 38 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Disparities from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Disparities

See all studies in Disparities →